Regulators

Drug Enforcement Administration, Diversion Control Division (DEA)

Federal agency

Each number links to the point's source. Points checked unless the point shows another date.

Remit

  • The Diversion Control Division's site takes online applications to obtain or renew a DEA registration and offers Ask REGIS, a chatbot released in beta, for general questions about DEA registration requirements and processes.1
  • Its home page notes that a waiver registration is no longer required to treat patients with opioid use disorder, and its registration menu links to the MATE Act training requirements.1
  • Under 21 U.S.C. 824(a) DEA may suspend or revoke a registration on findings that include material falsification of the application or an act that would make registration inconsistent with the public interest.2

Who it supervises

  • Only persons actually engaged in handling controlled substances, such as dispensing, must hold a registration (21 CFR 1301.11(a)); a practitioner must also have authority under the laws of the state where it practices to dispense controlled substances.3
  • A practitioner with a professional practice location in more than one state must obtain a separate DEA registration in each of those states; a DEA registration based on a state license cannot authorize controlled substance dispensing outside that state.3

How it examines

  • A registrant must notify the DEA Field Division Office in its area, in writing, of any theft or significant loss of controlled substances within one business day of discovery, and file a complete DEA Form 106 within 45 days (21 CFR 1301.76(b)).4
  • Before denying, revoking or suspending a registration, DEA serves an Order to Show Cause; the registrant may submit a corrective action plan, which DEA reviews to decide whether to discontinue or defer the proceedings (21 U.S.C. 824(c)).2

Technology and security guidance

  • DEA's telemedicine page says it is drafting updated regulations for telemedicine; it held public listening sessions on September 12 and 13, 2023, receiving comments from 58 practitioners, experts, advocates, patients and others.5

Recent rules

  • Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (DEA with HHS, published December 31, 2025): effective January 1, 2026 through December 31, 2026, DEA-registered practitioners may prescribe schedule II to V controlled substances by telemedicine to a patient they have not evaluated in person, if the rule's conditions are met.6
  • The extension cites the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, with the telemedicine definition at 21 U.S.C. 802(54) and the in-person evaluation requirement at 21 U.S.C. 829(e).6
  • Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed January 17, 2025) would establish a special registration framework with three types of special registration and heightened prescription, recordkeeping and reporting requirements. Proposed, as checked on 2026-11-14.7
  • The final rules on buprenorphine treatment via telemedicine and on continuity of care via telemedicine for Veterans Affairs patients, first published January 17, 2025: the extension published December 31, 2025 states that they go into effect on December 31, 2025.6

Enforcement

What the regulator's own pages say about its enforcement. Not a count or a pattern of actions.

  • DEA calls Orders to Show Cause and Immediate Suspension Orders its administrative actions; it may issue them when it finds a registrant has violated the Controlled Substances Act.2
  • An Immediate Suspension Order under 21 U.S.C. 824(d) is used where there is imminent danger to public health or safety, meaning a substantial likelihood of an immediate threat of death, serious bodily harm or abuse of a controlled substance.2
  • The Division's What's New page posts Decision and Order documents in registrant cases, the latest dated November 12, 2026 as checked on 2026-11-14.8

Official channels

Links to the regulator's own pages, checked .

Get the data: JSON

License: CC BY 4.0. Underlying government texts are public domain or under their own terms. Attribute "Moraph Insights" with a link to the page.

Sources

  1. Drug Enforcement Administration, Diversion Control Division. DEA Diversion Control Division (home page). Checked .
  2. Drug Enforcement Administration, Diversion Control Division. Administrative Actions. Checked .
  3. Drug Enforcement Administration, Diversion Control Division. Registration Q&A. Checked .
  4. Office of the Federal Register (eCFR). 21 CFR 1301.76, Other security controls for practitioners (eCFR). Checked .
  5. Drug Enforcement Administration, Diversion Control Division. Telemedicine. Checked .
  6. Drug Enforcement Administration and Department of Health and Human Services (Federal Register). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, Federal Register document 2025-24123 (December 31, 2025; govinfo). Checked .
  7. Drug Enforcement Administration (Federal Register). Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, document 2025-01099 (January 17, 2025; abstract opened through the Federal Register API). Checked .
  8. Drug Enforcement Administration, Diversion Control Division. What's New. Checked .

How we source and check every fact: Editorial standards · Corrections

Last reviewed .

Spotted an error? Tell us and we will check it and correct the page where needed.